MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- ALEMBIC PHARMA - CIPLA
ALEMBIC PHARMA vs CIPLA - Comparison Results
Current Valuations
| ALEMBIC PHARMA | CIPLA | ALEMBIC PHARMA/ CIPLA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 19.4 | 35.9 | 54.2% | View Chart |
| P/BV | x | 7.5 | 4.2 | 180.3% | View Chart |
| Dividend Yield | % | 0.5 | 0.5 | 103.4% |
Financials
 ALEMBIC PHARMA  CIPLA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ALEMBIC PHARMA Mar-19 |
CIPLA Mar-20 |
ALEMBIC PHARMA/ CIPLA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 664 | 586 | 113.4% | |
| Low | Rs | 412 | 357 | 115.6% | |
| Sales per share (Unadj.) | Rs | 208.7 | 207.0 | 100.8% | |
| Earnings per share (Unadj.) | Rs | 31.0 | 18.6 | 166.7% | |
| Cash flow per share (Unadj.) | Rs | 37.1 | 33.2 | 111.9% | |
| Dividends per share (Unadj.) | Rs | 5.50 | 4.00 | 137.5% | |
| Dividend yield (eoy) | % | 1.0 | 0.8 | 120.4% | |
| Book value per share (Unadj.) | Rs | 144.2 | 195.5 | 73.8% | |
| Shares outstanding (eoy) | m | 188.52 | 806.35 | 23.4% | |
| Bonus/Rights/Conversions | - | ESOS | - | ||
| Price / Sales ratio | x | 2.6 | 2.3 | 113.3% | |
| Avg P/E ratio | x | 17.4 | 25.3 | 68.5% | |
| P/CF ratio (eoy) | x | 14.5 | 14.2 | 102.1% | |
| Price / Book Value ratio | x | 3.7 | 2.4 | 154.8% | |
| Dividend payout | % | 17.7 | 21.5 | 82.5% | |
| Avg Mkt Cap | Rs m | 101,461 | 379,912 | 26.7% | |
| No. of employees | `000 | NA | 25.8 | 0.0% | |
| Total wages/salary | Rs m | 7,467 | 30,270 | 24.7% | |
| Avg. sales/employee | Rs Th | NM | 6,459.6 | - | |
| Avg. wages/employee | Rs Th | NM | 1,171.2 | - | |
| Avg. net profit/employee | Rs Th | NM | 580.2 | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 39,347 | 166,949 | 23.6% | |
| Other income | Rs m | 94 | 3,442 | 2.7% | |
| Total revenues | Rs m | 39,441 | 170,391 | 23.1% | |
| Gross profit | Rs m | 8,736 | 32,060 | 27.2% | |
| Depreciation | Rs m | 1,152 | 11,747 | 9.8% | |
| Interest | Rs m | 184 | 1,974 | 9.3% | |
| Profit before tax | Rs m | 7,493 | 21,782 | 34.4% | |
| Minority Interest | Rs m | 11 | -475 | -2.3% | |
| Prior Period Items | Rs m | -93 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 1,568 | 6,312 | 24.8% | |
| Profit after tax | Rs m | 5,844 | 14,995 | 39.0% | |
| Gross profit margin | % | 22.2 | 19.2 | 115.6% | |
| Effective tax rate | % | 20.9 | 29.0 | 72.2% | |
| Net profit margin | % | 14.9 | 9.0 | 165.4% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 19,577 | 117,038 | 16.7% | |
| Current liabilities | Rs m | 14,896 | 43,931 | 33.9% | |
| Net working cap to sales | % | 11.9 | 43.8 | 27.2% | |
| Current ratio | x | 1.3 | 2.7 | 49.3% | |
| Inventory Days | Days | 90 | 96 | 93.8% | |
| Debtors Days | Days | 45 | 85 | 53.3% | |
| Net fixed assets | Rs m | 27,097 | 107,424 | 25.2% | |
| Share capital | Rs m | 377 | 1,613 | 23.4% | |
| "Free" reserves | Rs m | 26,811 | 156,018 | 17.2% | |
| Net worth | Rs m | 27,188 | 157,630 | 17.2% | |
| Long term debt | Rs m | 4,993 | 23,693 | 21.1% | |
| Total assets | Rs m | 47,778 | 236,626 | 20.2% | |
| Interest coverage | x | 41.7 | 12.0 | 346.5% | |
| Debt to equity ratio | x | 0.2 | 0.2 | 122.2% | |
| Sales to assets ratio | x | 0.8 | 0.7 | 116.7% | |
| Return on assets | % | 12.6 | 7.2 | 175.9% | |
| Return on equity | % | 21.5 | 9.5 | 225.9% | |
| Return on capital | % | 23.6 | 12.8 | 183.8% | |
| Exports to sales | % | 0 | 33.0 | 0.0% | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | 55,175 | 0.0% | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 19,453 | 56,036 | 34.7% | |
| Fx outflow | Rs m | 6,065 | 6,764 | 89.7% | |
| Net fx | Rs m | 13,388 | 49,272 | 27.2% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 8,120 | 30,685 | 26.5% | |
| From Investments | Rs m | -7,556 | 1,040 | -726.3% | |
| From Financial Activity | Rs m | 590 | -29,488 | -2.0% | |
| Net Cashflow | Rs m | 1,153 | 2,340 | 49.3% | |
Share Holding
| Indian Promoters | % | 74.1 | 16.0 | 463.1% | |
| Foreign collaborators | % | 0.0 | 20.8 | - | |
| Indian inst/Mut Fund | % | 2.9 | 12.2 | 23.8% | |
| FIIs | % | 9.1 | 23.7 | 38.4% | |
| ADR/GDR | % | 0.0 | 1.1 | - | |
| Free float | % | 13.9 | 26.2 | 53.1% | |
| Shareholders | 49,328 | 161,166 | 30.6% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ALEMBIC PHARMA With: GSK PHARMA JUBILANT LIFE SCIENCES DIVIS LABORATORIES PIRAMAL ENTERPRISES NATCO PHARMA
Compare ALEMBIC PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Today's Market
Sensex Zooms 450 Points in Opening Trade; Mindtree Up 5% Post Q3 Results(09:30 am)
Asian share markets and US stock futures are trading higher today as investors awaited comments from Joe Biden's Treasury Secretary nominee Janet Yellen on US stimulus and the dollar.
Related Views on News
CIPLA 2019-20 Annual Report Analysis (Annual Result Update)
Nov 4, 2020 | Updated on Nov 4, 2020Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)
Oct 23, 2020 | Updated on Oct 23, 2020For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)
Aug 10, 2020 | Updated on Aug 10, 2020For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.
CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)
May 19, 2020 | Updated on May 19, 2020For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.
CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)
Feb 6, 2020 | Updated on Feb 6, 2020For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.
More Views on NewsMost Popular
'Essential' Smallcap Stock Recommendations(Profit Hunter)
Jan 8, 2021The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
Is Nifty Forming a Top(Fast Profits Daily)
Jan 8, 2021The charts are telling the bulls to be cautious.
Why Gold Hit Lower Circuit(Fast Profits Daily)
Jan 11, 2021Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)
Jan 11, 2021Our ace stock picker is ready to capitalise on a big growth opportunity.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
ALEMBIC PHARMA SHARE PRICE
Jan 19, 2021 10:16 AM
TRACK ALEMBIC PHARMA
- Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ALEMBIC PHARMA
ALEMBIC PHARMA - J.B.CHEMICALS COMPARISON
COMPARE ALEMBIC PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.